Organizational, or Other Financial Benefit
|Jeffrey L. Anderson, Co-Chair||Intermountain Medical Center—Associate Chief of Cardiology||None||None||None||None||None||None|
|Paul A. Heidenreich, Co-Chair||VA Palo Alto Medical Center—Professor of Medicine||None||None||None||None||None||None|
|Paul G. Barnett||VA Palo Alto Medical Center—Director||None||None||None||None||None||None|
|Mark A. Creager||Brigham and Women’s Hospital Cardiovascular Division—Professor||None||None||None||None||None||None|
|Gregg C. Fonarow||Ahmanson−UCLA Cardiomyopathy Center—Director, Division of Cardiology||None||None||None||None||None||None|
|Raymond J. Gibbons||Mayo Clinic—Professor of Medicine and Co-Director, Nuclear Cardiology Lab||None||None||None||None||None||None|
|Jonathan L. Halperin||Mount Sinai Medical Center—Professor of Medicine||None||None||None||None||None||None|
|Mark A. Hlatky||Stanford University School of Medicine—Professor of Health Research and Policy||None||None||None||None||None||None|
|Alice K. Jacobs||Boston University Medical Center—Professor of Medicine and Director of Cath Lab, Division of Cardiology||None||None||None||None||None||None|
|Daniel B. Mark||Duke Clinical Research Institute—Professor of Medicine||None||None||None||None||None||None|
|Frederick A. Masoudi||University of Colorado at Denver—Associate Professor of Medicine, Division of Cardiology||None||None||None||None||None||None|
|Eric D. Peterson||Duke Clinical Research Institute and Duke University Medical Center—Professor of Medicine and Director, Cardiovascular Outcomes||None||None||None||None||None||None|
|Leslee J. Shaw||Emory University School of Medicine—Professor of Medicine||None||None||None||None||None||None|
This table represents the relationships of committee members with industry and other entities that were determined to be relevant to this document. A person is deemed to have a significant interest in a business if the interest represents ownership of > 5% of the voting stock or share of the business entity, or ownership of >$10,000 of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person’s gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted. Please refer to http://www.cardiosource.org/Science-And-Quality/Practice-Guidelines-and-Quality-Standards/Relationships-With-Industry-Policy.aspx for definitions of disclosure categories or additional information about the ACC Disclosure Policy for Writing Committees.
According to the ACC/AHA, a person has a relevant relationship IF: a) The relationship or interest relates to the same or similar subject matter, intellectual property or asset, topic, or issue addressed in the document; or b) The company/entity (with whom the relationship exists) makes a drug, drug class, or device addressed in the document, or makes a competing drug or device addressed in the document; or c) The person or a member of the person’s household, has a reasonable potential for financial, professional or other personal gain or loss as a result of the issues/content addressed in the document.